Verification evidence is still being completed.
PDF / print export
Oncopeptides
Stockholm, Sweden
- Verified lead
- Jakob Lindberg
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Oncology, Peptide-Drug Conjugates, Cancer Therapeutics, and Clinical Drug Development
- Review cycle
- May 2026
- Full address
- Luntmakargatan 46, 111 37 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Oncopeptides company material confirming the Luntmakargatan 46 Stockholm address.
- Editorial note
- Oncopeptides is published because official company materials confirm current leadership, Stockholm operating address, and a clear oncology therapeutics platform.
Oncology, Peptide-Drug Conjugates, Cancer Therapeutics, and Clinical Drug Development
Official leadership disclosure, Official Stockholm address disclosure, Clinical oncology platform claim
Oncopeptides is published because official company materials confirm current leadership, Stockholm operating address, and a clear oncology therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
Oncopeptides
Oncology, Peptide-Drug Conjugates, Cancer Therapeutics, and Clinical Drug Development · Clinical-stage therapeutics platform
Oncopeptides runs oncology drug development, clinical therapeutics programs, and targeted cancer treatment platforms in Stockholm, Sweden.
- Lead
- Jakob Lindberg (verified ↗)
- Address
- Luntmakargatan 46, 111 37 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Oncology Drug Development · Clinical Therapeutics Programs · Targeted Cancer Treatment Platforms
- Founded
- 2000
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Jakob Lindberg
CEO
Full addressLuntmakargatan 46, 111 37 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Oncopeptides company material listing the Luntmakargatan 46 Stockholm address.
Open sourceClinical-stage therapeutics platform
Stockholm, Sweden. Oncology, Peptide-Drug Conjugates, Cancer Therapeutics, and Clinical Drug Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Stockholm address disclosure, Clinical oncology platform claim
Oncology, Peptide-Drug Conjugates, Cancer Therapeutics, and Clinical Drug Development
Oncopeptides is published because official company materials confirm current leadership, Stockholm operating address, and a clear oncology therapeutics platform.
Editorial note
Oncopeptides is published because official company materials confirm current leadership, Stockholm operating address, and a clear oncology therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Oncology Drug Development
Clinical Therapeutics Programs
Targeted Cancer Treatment Platforms
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Oncology program workflow
Clinical development systems
Therapeutics R&D infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Oncopeptides located?
- Oncopeptides operates from Luntmakargatan 46, 111 37 Stockholm, Sweden, Stockholm, Sweden.
- Who runs Oncopeptides?
- Oncopeptides is led by Jakob Lindberg, CEO. Verified 21 Mar 2026.
- What does Oncopeptides do?
- Oncopeptides runs oncology drug development, clinical therapeutics programs, and targeted cancer treatment platforms in Stockholm, Sweden. Core capabilities: Oncology Drug Development, Clinical Therapeutics Programs, Targeted Cancer Treatment Platforms.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.